CG Bio Shows UBE Spine Tools to Australian Surgeons
The regenerative medicine company displayed its displayed instruments and imaging equipment, with market entry depending on each country's licensing approvals.
Updated on Nov. 6, 2026 in Biotech

CG Bio, a global regenerative medicine company, participated as a gold sponsor in the 2026 World UBE Society Australia Annual Congress in Melbourne, operating an exhibition booth at the RACV City Club from October 23 to 25. The company showed products including the UBE instrument set Multifocus, the 4K imaging system ELICA 4K, and several spinal and bone graft products; these are displayed products, and the stub does not state their regulatory or commercial availability.
Why it matters
CG Bio is using an existing distribution relationship for its bone substitute Novosis in New Zealand to pursue additional biologics and spinal implant introductions in Australia and New Zealand. The move reflects a pattern of regenerative medicine firms extending from a single product into a broader portfolio in the spine surgery market.
The displayed portfolio includes the Multifocus UBE surgical instrument set from subsidiary CG MedTech, the ELICA 4K imaging system from Solendos, the Colonnade pedicle screw system, the Xcender height-expandable spinal cage, and the Novosis and Bongener and Allomix bone graft materials. The source does not provide performance specifications, benchmarks, or comparisons for any of these products.
The players
CG Bio
A global regenerative medicine company whose portfolio spans UBE surgical instruments through subsidiary CG MedTech, spinal implants, and bone graft materials.
LifeHealthcare
An Australian medical device distributor that currently brings CG Bio's Novosis bone substitute to the New Zealand market.
The details
The congress focuses on Unilateral Biportal Endoscopy, a minimally invasive spine surgery technique in which a surgeon works through two small portals, one for an endoscope camera and one for instruments. CG Bio's exhibit centered on instruments and imaging equipment built for this approach, which the company says is intended to supply the complete set of tools an operating room needs rather than individual items. The company's strategy is to gradually adjust its market entry for UBE-related instruments and imaging equipment according to each country's licensing approvals and distribution conditions.
Timeline
October 23 to 25, 2026: CG Bio operates its exhibition booth at the RACV City Club in Melbourne.
2026: The World UBE Society Australia Annual Congress takes place in Melbourne.
The Tech Race
CG Bio is positioning its UBE-dedicated Multifocus instrument set and ELICA 4K imaging system alongside its spinal implant lines in a single market push. The source does not name specific competing firms or competing UBE products, so the competitive comparison cannot be drawn from the extraction.
Surgeons and hospitals in Australia and New Zealand would see these products only as their availability is confirmed through distributors and licensing approvals, which the source does not give a timeline for. The displayed products are not described as currently usable in those markets.
The takeaway
Watch for announcements from LifeHealthcare or CG Bio on regulatory licensing or product launches in Australia and New Zealand, which would show whether the UBE instrument and imaging lines move from displays to distributed products. Track whether the planned biologics and spinal implant introductions are named in future distributor agreements.
Further reading
For broader context on the research and products shaping this field, explore the latest in Biotech.
Source note: This article includes information reported by Business Korea.


